Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review (Q30393860)

13 September 2017

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review (English)

1 reference

adaptive radiation therapy

13 September 2017

0 references

4

Michael McDermott

0 references

Thomas J Kaley

object named as

Thomas Kaley

1

0 references

Patrick Y Wen

11

object named as

Patrick Wen

1 reference

13 September 2017

5

Katherine Panageas

1 reference

13 September 2017

Igor Barani

2

1 reference

13 September 2017

Marc Chamberlain

3

1 reference

13 September 2017

Jeffrey Raizer

6

1 reference

13 September 2017

Leland Rogers

7

1 reference

13 September 2017

David Schiff

8

1 reference

13 September 2017

Michael Vogelbaum

9

1 reference

13 September 2017

Damien Weber

10

1 reference

13 September 2017

language of work or name

1 reference

4 February 2014

1 reference

13 September 2017

1 reference

13 September 2017

16

1 reference

13 September 2017

6

1 reference

13 September 2017

829-840

1 reference

Atypical and anaplastic meningiomas treated with bevacizumab.

13 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Response Assessment in Neuro-Oncology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Medical therapies for meningiomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Advances in meningioma therapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Hydroxyurea treatment of meningiomas: a pilot study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Salvage chemotherapy with CPT-11 for recurrent meningioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Temozolomide for treatment-resistant recurrent meningioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Adjuvant combined modality therapy for malignant meningiomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Antiestrogenic therapy of meningiomas--a pilot study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Treatment of meningioma with octreotide

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

The role of progesterone receptors in meningioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

The significance of artificial cerebrospinal fluid as perfusate and endoneurosurgery

20 June 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Non-resectable slow-growing meningiomas treated by hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Hypothalamic amnesia and frontal lobe function disorders after Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Treatment of high risk or recurrent meningiomas with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Red blood cell morphology in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/NEUONC/NOT330

Meningioma of the optic nerve sheath: treatment with hydroxyurea

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

Response criteria for phase II studies of supratentorial malignant glioma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022224

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

26 November 2018

1 reference

12 December 2020

Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma

1 reference

12 December 2020

Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases

1 reference

12 December 2020

Bevacizumab-induced regression of anaplastic meningioma

1 reference

12 December 2020

Successful treatment of meningioma with octreotide

1 reference

12 December 2020

Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay

1 reference

12 December 2020

Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab

1 reference

12 December 2020

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue

1 reference

12 December 2020

Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

1 reference

12 December 2020

Adjuvant therapy for unresectable meningiomas: benign and malignant

1 reference

12 December 2020

Hydroxyurea chemotherapy for unresectable or residual meningioma

1 reference

12 December 2020

Visual improvement during octreotide therapy in a case of episellar meningioma

1 reference

12 December 2020

Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series

1 reference

12 December 2020

Clinical use of octreotide in unresectable meningiomas. A report of three cases

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOT330

1 reference

13 September 2017

1 reference

13 September 2017

PubMed publication ID

24500419

1 reference